News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
Second interchangeable biosimilar product approved by agency
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
Subscribe To Our Newsletter & Stay Updated
